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Abstract
Aim: To investigate the relationship between metabolic parameters and thyroid hormone changes which occur in patients
treated with thyroid replacement therapy following total thyroidectomy.
Material and Method: The study comprised 30 patients who underwent total thyroidectomy. Evaluations were made
preoperatively and after 6 and 12 months postoperatively. Body mass index was calculated by recording height and weight of
all patients, waist size was measured, arterial blood pressure was measured with a sphyngomanometer on the right arm after
10 mins of rest. Peripheral blood samples were taken after 12-hour fasting for the evaluation of low density lipoprotein, high
density lipoprotein, total cholesterol, triglyceride, fasting glucose, fasting insulin, thyroid stimulating hormone, free T3, free T4,
C-reactive protein, and haemoglobin A1c values.
Results: In the postoperative 1-year follow-up, a significant increase was determined in total cholesterol, low-density protein
and triglyceride levels, which are related to cardiovascular risk, but no significant change was determined in high density
protein levels. In addition, a significant increase was determined in the postoperative trend of both systolic and diastolic
arterial blood pressures compared to the preoperative values.
Conclusion: Although euthyroid was achieved with follow-up of thyroid functions in the patients who underwent bilateral total
thyroidectomy, it was found that there could be changes in metabolic parameters. Therefore, with close monitoring of the
metabolic profile of these patients, it can be recommended that lifestyle changes are made when medical intervention is
insufficient.
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Introduction
Thyroidectomy, meaning the complete or partial removal of
a diseased thyroid gland, is still among the most frequently
applied surgical interventions in general surgery clinics. The
follow-up and treatment of complications which may develop
associated with postoperative thyroid hormone changes is as
important as attempting to prevent surgery-related complica-
tions following thyroidectomy [1-3].
Thyroid hormones expressed by the thyroid gland, are in
a general sense, hormones which regulate basal metabolism.
Thyroid hormones affect carbohydrate, protein, fat and cal-
cium metabolism and the cardiovascular, gastro-intestinal,
hematopoietic, pulmonary and neuromuscular systems. The
effects of thyroid disease on the cardiovascular system have
been investigated by many researchers. These studies have
revealed various negative effects on the cardiovascular system
of low or very high values of thyroid hormone levels [4]. In
addition, there are various ongoing studies on the effects of
low, normal or over-expression of these hormones on lipid
metabolism and cholesterol levels. To date there have been
few studies, although there is increasing interest in another
subject, which is the changes observed in body weight, waist
circumference and body mass index (BMI) values when there
is thyroid hormone deficiency or excess [5, 6].
The definition of the collective risk factors is required
for evaluation of the development of metabolic syndrome,
Type 2 diabetes and cardiovascular complications. Previous
prospective studies, using various definitions of metabolic
syndrome, have suggested that the development of the syn-
drome is associated with a combination of factors. The factors
focussed on are in particular insulin, obesity, lifestyle and
healthcare habits. Reduced insulin sensitivity is thought to be
at the forefront of the development of metabolic syndrome.
Factors playing a role in the pathogenesis include obesity,
insulin resistance, atherogenic dyslipidemia, inflammation
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due to coexisting morbidity, thrombosis and carcinogenesis
[7-11].
The aim of this study was to investigate the changes in
metabolic parameters and thyroid hormones despite thyroid
replacement therapy following bilateral total thyroidectomy.
1. Material and Methods
The study comprised 36 patients who underwent bilateral
total thyroidectomy in the General Surgery Clinic of Izmir
Bozyaka Training and Research Hospital between October
2011 and May 2012. Informed consent was obtained from all
patients. Evaluations of the patients were made preoperatively
and at 6 months and 12 months postoperatively. Due to non-
attendance of the 6-month follow-up appointment, 6 patients
were withdrawn from the study.
All patients were evaluated preoperatively. Body mass
index was calculated by recording height and weight of all
patients, waist size was measured, arterial blood pressure
was measured with a sphyngomanometer on the right arm
after 10 mins of rest and a record was made of medications
used. Peripheral blood samples were taken after 12-hour
fasting for the analysis of low density lipoprotein (LDL),
high density lipoprotein (HDL), total cholesterol (TChol),
triglyceride (TG), fasting glucose, fasting insulin, thyroid
stimulating hormone (TSH), free T3 (FT3), free T4 (FT4),
C-reactive protein (CRP), and haemoglobin A1c (HbA1C)
values. To evaluate insulin resistance, the homeostatic model
assessment (HOMA-IR) test was used. The test was calculated
according to the formula:
HOMA− IR= (Fasting insulin (mU/l)x
fasting plasma glucose (mg/dl))/405 (1)
All patients started thyroid replacement therapy (L-thyroxin)
2 weeks postoperatively.
All these steps were repeated at the 6 and 12-month follow-
up examinations. The data for each patient were recorded on
a case report form.
Statistical Analysis
Statistical analysis was made using the SAS system program.
Variance analysis was applied for the evaluation of continu-
ous variables between groups. If the variance analysis was
homogenous, repeated ANOVA was applied, and if not homge-
nous, the Friedman test. Subgroup analysis was made between
paired groups and if the variance analysis was homogenous,
repeated ANOVA was applied, and if not homgenous, the
Wilcoxon score test. A value of p<0.05 was accepted as
statistically significant in all the analyses.
2. Results
The basal characteristic properties of the patients were eval-
uated (Table 1). The patients were 25 females (83.3%) and
5 males (16.6%) with a mean age of 55 ± 13.8 years. The
diagnoses were hypertension in 12 (40%) patients, diabetes
mellitus in 7 (23%), coronary artery disease in 2 (6.6%) and
hyperlipidemia in 3 (10%). No chronic renal disease was
found in any patient. Medications used by the patients were
B-blockers in 4, (13.3%), ACE inhibitor or angiotensin recep-
tor antagonist in 9 (29.9%), thyazide diuretics in 4 (13.3%),
oral anti-diabetics in 6 (20%) and insulin in 1 (3.3%).
Table 1. Baseline characteristics.
Age 55 ± 13.8
Gender Female 25 (%83.3)Male 5 (%16.6 )
Hypertension 12 (%40)
Diabetes mellitus 7 (%23)
Coronary artery disease 2 (%6.6)
Hyperlipidemia 3 (%10)
Used drugs
B-blockers 4 (%13.3)
ACEI/ARBs 9 (%29.9)
Thiazide diuretics 4 (%13.3)
Oral antidiabetic 6 (%20)
Insulin 1 (%3.3)
Note.
ACEI : angiotensin-coverting enzyme inhibitors;
ARBs : Angiotensin receptor blockers.
The patients were operated on for multinodular goitre
(MNG) in 23 cases (76.6%), suspected malignancy of the
nodule in 4 (13.3%) and Graves disease in 3 (10%). Preopera-
tive and postoperative 6 and 12 months data analysis of the
patients is shown in Table 2.
The TSH values were determined as pre-operative 1.20
± 3.45uIU/ml, postoperative 6th month, 1.28 ± 15.3 uIU/ml
and postoperative 12th month 1.65 ± 8.4 uIU/ml, with no
statistically significant difference between them.
The FT3 values were determined as preoperative 3.06 ±
0.45 pg/ml, postoperative 6th month 2.79 ± 0.53 pg/ml and
postoperative 12th month, 2.8± 0.29 pg/ml. Although a slight
reduction was observed in the postoperative FT3 values, the
difference between the preoperative and postoperative values
was statistically significant.
The FT4 values were determined as preoperative 0.81 ±
0.14 pg/ml, postoperative 6th month 0.96 ± 0.27 pg/ml and
postoperative 12th month, 0.98± 0.2 pg/ml. Although a slight
increase was observed in the postoeprative FT3 values, the
difference between the preoperative and postoperative values
was statistically significant (Table 2).
The TChol values were determined as preoperative 191.2
± 31.7mg/dl, postoperative 6th month 204.7 ± 32.8 mg/dl,
and postoperative 12th month, 203.9 ± 27 mg/dl. When pre-
operative and postoperative values were compared, a statisti-
cally significant difference was determined, but the difference
between the 6th and 12th months postoperatively was not
statistically significant.
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Table 2. Preoperative and 6th and 12th months postoperative data analysis.
Preoperative Postoperative
(6th months)
Postoperative
(12th months)
p1 p2 p3
TSH* (uIU/ml) 1.20 ± 3.45 1.28 ± 15.3 1.65 ± 8.4 NS NS NS
FT3 (pg/ml) 3.06 ± 0.45 2.79 ± 0.53 2.8 ± 0.29 0.02 0.006 NS
FT4 (ng/ml) 0.81 ± 0.14 0.96 ± 0.27 0.98 ± 0.2 0.003 0.0002 NS
TChol (mg/dl) 191.2 ± 31.7 204.7 ± 32.8 203.9 ± 27 0.008 0.02 NS
TG (mg/dl) 119.4 ± 52.4 138 ± 61.4 131.4 ± 77.1 NS NS NS
HDL (mg/dl) 53.6 ± 12.2 52.7 ± 12.3 54 ± 11.7 NS NS NS
LDL (mg/dl) 118 ± 27 137.8 ± 32.2 133.4 ± 24.9 0.0003 0.002 NS
BMI (kg/m2) 29.2 ± 4.8 30.05 ± 5.05 29.9 ± 4.9 0.0012 0.02 NS
Kilo (kg) 75.9 ± 14.09 78.03 ± 14.8 77.5 ± 13.8 0.001 0.03 NS
Waist circumference (cm) 101.2 ± 11.4 103.1 ± 11.2 105.2 ± 12 <0.001 <0.001 0.0019
Fasting glucose values * (mg/dl) 110.7 ± 31.1 102 ± 19.9 107.9 ± 26.5 NS NS NS
Fasting insulin values * (uU/ml) 9.03 ± 12.8 7.73 ± 4.09 7.19 ± 6.04 NS NS NS
HbA1c (%) 5.92 ± 0.7 5.96 ± 0.6 5.97 ± 0.6 NS NS NS
HOMA-IR* 2.07 ± 4.03 1.84 ± 1.32 1.72 ± 2.63 NS NS NS
CRP* (mg/dl) 1.56 ± 3.57 0.33 ± 0.2 0.31 ± 0.61 0.005 <0.001 0.03
Systolic arterial blood (mmHg) 118.6 ± 11.6 127.6 ± 20 125.8 ± 18.5 0.0014 0.0079 NS
Diastolic arterial blood (mmHg) 76 ± 8.5 84.5 ± 13.6 83.1 ± 13.03 0.0006 0.0016 NS
Note.
p1 : Preoperative - posptoperative (6th months);
p2 : Preoperative- posptoperative (12th months);
p3 : Postoperative (6th months) - postoperative (12th months);
NS : Not significant;
TSH : Thyroid stimulating hormone;
FT3 : Free T3;
FT4 : Free T4;
TChol : Total cholesterol;
TG : Triglyceride;
HDL : High-density lipoprotein;
LDL : Low-density lipoprotein;
BMI : Body mass index;
HOMA-IR : Homeostatic model assessment;
CRP : C-reaktive protein;
* Median values were used (after Friedman analysis), the average values were used for other values.
The TG values were determined as preoperative 119.4 ±
52.4mg/dl, postoperative 6th month 138 ± 61.4 mg/dl, and
postoperative 12th month, 54± 11.7 mg/dl and no statistically
significant difference was determined.
The HDL values were determined as preoperative 53.6
± 12.2mg/dl, postoperative 6th month 52.7 ± 12.3 mg/dl,
and postoperative 12th month, 133.4 ± 24.9 mg/dl and no
statistically significant difference was determined.
The LDL values were determined as preoperative 118
± 27mg/dl, postoperative 6th month 137.8 ± 32.2 mg/dl,
and postoperative 12th month, 133.4 ± 24.9 mg/dl. When
preoperative and postoperative values were compared, a statis-
tically significant increase was determined, but the difference
between the 6th and 12th months postoperatively was not
statistically significant.
The BMI values were determined as preoperative 29.2
± 4.8 kg/m2, postoperative 6th month 30.05 ± 5.05 kg/m2
and postoperative 12th month, 29.9 ± 4.9 kg/m2. Although a
slight increase was observed in the postoperative BMI values,
the difference between the preoperative and postoperative val-
ues was statistically significant. In addition, the body weights
of the patients were determined as preoperative 75.9 ± 14.09
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kg, postoperative 6th month 78.03 ± 14.8 kg and postoper-
ative 12th month 77.5 ± 13.8 kg. When preoperative and
postoperative values were compared, a statistically signifi-
cant increase was determined, but the difference between the
6th and 12th months postoperatively was not statistically sig-
nificant. The waist circumference values were measured as
preoperative 101.2 ± 11.4 cm, postoperative 6th month 103.1
± 11.2 cm and postoperative 12th month 105.2 ± 12 cm. The
difference between preoperative and postoperative values was
determined to be statistically significant (Table 2).
The fasting insulin values were determined as pre-operative
9.03 ± 12.8uIU/ml, postoperative 6th month, 7.73 ± 4.09
uIU/ml and postoperative 12th month 7.19 ± 6.04 uIU/ml,
with no statistically significant difference between them.
The HbA1c values of the patients were determined as
pre-operative 5.92 ± 0.7% postoperative 6th month, 5.96 ±
0.6% and postoperative 12th month 5.97 ± 0.6% with no
statistically significant difference between them.
The HOMA-IR values were determined as pre-operative
2.07 ± 4.03, postoperative 6th month, 1.84 ± 1.32 and post-
operative 12th month 1.72 ± 2.63, with no statistically signif-
icant difference between them.
The CRP values were calculated as preoperative 1.56 ±
3.57mg/dl, postoperative 6th month 0.33 ± 0.2 mg/dl, and
postoperative 12th month, 0.31± 0.61 mg/dl and a statistically
significant difference was determined in the comparison of
the preoperative and postoperative values (Table 2).
The systolic arterial blood pressure values were measured
as preoperative 118.6 ± 11.6mmHg, postoperative 6th month
127.6 ± 20mmHg, and postoperative 12th month, 125.8 ±
18.5 mmHg. When preoperative and postoperative values
were compared, a statistically significant increase was deter-
mined, but the difference between the 6th and 12th months
postoperatively was not statistically significant.
The diastolic arterial blood pressure values were measured
as preoperative 76 ± 8.5mmHg, postoperative 6th month 84.5
± 13.6mmHg, and postoperative 12th month, 83.1 ± 13.03
mmHg. When preoperative and postoperative values were
compared, a statistically significant increase was determined,
but the difference between the 6th and 12th months postoper-
atively was not statistically significant.
The fasting glucose values were determined as preopera-
tive 110.7 ± 31.1mg/dl, postoperative 6th month 102 ± 19.9
mg/dl, and postoperative 12th month, 107.9 ± 26.5 mg/dl and
no statistically significant difference was determined (Table
2).
3. Discussion
In the this study the metabolic profiles of patients who under-
went bilateral total thyroidectomy were examined preopera-
tively and in 6 and 12 months postoperatively. The aim of the
study was to analyse changes developing in the postoerative
period.
No statistically significant difference was determined be-
tween the preoperative TSH values and those at 6 and 12
months postoperatively. While a slight decrease in postopera-
tive FT3 values was determined compared to the preoperative
values, an increase was determined in the postoperative FT4
values. These changes are thought to be due to thyroid re-
placement therapy.
Various risk evaluation systems have been developed to
be able to calculate the risk of a cardiovascular event devel-
oping in a healthy individual (myocardial infarction, stroke,
atherosclerotic events which may lead to results such as sud-
den cardiac death). Some of these currently available systems
are Framingham, SCORE, ASSIGN, Q-Risk, PROCAM and
WHO [12, 13].
In a NHANES III study, 11611 healthy cases were sepa-
rated into groups of low, moderate and high risk for a cardio-
vascular event. The Framingham risk evaluation system was
developed based on the data of that study. The basis of the
Framingham risk evaluation system is the evaluation of TChol,
HDL, systolic blood pressure, age, gender, and cigarette use
[14].
In 2004, the NHANES III study was re-analysed taking
metabolic syndrome criteria into account. In cases determined
with metabolic syndrome, the risk of myocardial infarction
and /or stroke was determined to be significantly higher [15].
In a TEKHARF study conducted in Turkey, 53% of patients
who developed coronary artery disease were determined to
have metabolic syndrome [16].
In the dyslipidemia guidelines published by the European
Cardiology Society (ESC) in 2011, the SCORE risk evaluation
system was recommended for the prediction of cardiovascu-
lar events. By evaluating age, gender, TChol, HDL, systolic
blood pressure and cigarette smoking, the 10-year develop-
ment risk of an atherosclerotic event is calculated in this risk
evaluation system. According to the risk scores, cases are
separated into risk groups of low risk (estimated 10-year risk
<1%), moderate risk (estimatd 10-year risk 1-4%), high risk
(estimated 10-year risk 5-9%) and very high risk (estimated
10-year risk ≥10%). In addition, those with a previous diag-
nosis of coronary artery disease, or with Type 2 diabetes, or
with moderate-severe chronic renal disease (glomerular filtra-
tion rate <60 ml/min/1.73 m2) are included in the very high
risk group. After defining the risk levels, various treatment
recommendations, primarily lifestyle changes to prevent car-
diovascular events, are presented together with the treatment
targets [17].
The results of the current study showed a significant in-
crease over the postoperative year in TChol, LDL and TG
levels, which have been correlated to the risk of a cardiovas-
cular event, but no significant change was determined in HDL
levels. It was also determined in the current study, that there
was a significantly increasing trend in both systolic and dias-
tolic arterial blood pressure values when preoperative values
were compared with postoperative values.
Reduced sensitivity to insulin, or in other words, insulin
resistance has been related in many studies with increased risk
of atherosclerosis and carotid intima media thickness, even in
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healthy individuals [18, 19]. The method most widely used in
clinical practice to determine insulin resistance is the HOMA-
IR formula. In the current study, no statistically significant
difference was determined between the HOMA-IR values cal-
culated preoperatively and postoperatively. Furthermore, no
significant difference was determined in respect of fasting
glucose and HbA1c values in the comparison of preoperative
and postoperative values. Although a slight reduction was
determined in the fasting glucose levels of the patients post-
operatively compared to the preoperativve levels, this was not
statistically significant.
In a 2010 study by O¨zdemir et al, no change was deter-
mined in weight and BMI in 3 and 6 months follow-up in
patients who had undergone total thyroidectomy for benign
nodular goitre [20]. Similarly in the current study, no sig-
nificant change was determined in BMI in the preoperative
and postoperative periods. However, a significant increase
was seen in the postoperative weight and waist circumference
measurements compared to those of the preoperative period.
The CRP values, which had increased preoperatively be-
cause of the thyroid gland or environmental factors, showed a
statistically significant fall postoperatively.
In several previous studies of hypothyroidic patients, a
decrease in carotid intima media thickness and improvement
in endothelial functions and the lipid profile have been shown
after treatment with L-thyroxin [21-23]. In the current study,
although euthyroid was achieved with L-thyroxin treatment,
the disorder in the lipid profile continued in the postoperative
1-year follow-up period, systolic and diastolic arterial blood
pressures increased and waist circumference values continued
to increase. The negative effects of the metabolic profile of
temporary hypothyroid (before starting thyroid replacement
therapy) which develops in the postoperative acute period
could still have an effect in the long-term despite later starting
L-thyroxin therapy and this can be interpreted as L-thyroxin
therapy remaining insufficient to reverse these negative ef-
fects.
4. Conclusion
The results of this study showed that even if euthyroid is
achieved in patients following bilateral total thyroidectomy,
the lipid profile, blood pressure and BMI values show negative
changes in the postoperative period. Therefore, in postopera-
tive follow-up, these parameters must be closely monitored in
addition to the thyroid hormones and lifestyle changes should
be implemented and where necessary, medical treatment.
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